Background:Parkinson's disease is the most common form of Parkinsonism, which is a collective term for a variety of chronic neurological diseases. These are similar and are characterized by problems related to mobility. Hallmark of PD are the presence of Lewy bodies + neuronal cell death in pars compacta of the substantia nigra. Clinical features represent rigid muscular tone, rest tremor, postural instability and akinesia. Main effective symptomatic treatment consists of Dopamin agonists and Levodopa. Even though there is still need of a more potent treatment which inhibits the progression of PD.
Objective: Do Selegiline and Rasagiline exert neuroprotection beside symptomatic effect on Parkinson’s patients?
Method:The literature was obtained with help of my coordinator. Following approved resources were used: PubMed, Uptodate,“Tidsskrift for norsk legeforeningen”. Keywords used to initiate search were: Selegiline AND Parkinson, Rasagiline AND Parkinson, Neuroprotection in Parkinson, symptoms/treatment of Parkinson.
Conclusion:Experimental studies confirm the possible neuroprotective effect of Selegiline and Rasagiline. Clinical studies however show a bit controversial results. The dose of 10 mg Selegiline and 1 mg daily Rasagiline in the early treatment of Parkinson's disease appear to slow the progression of the disease. To achieve the neuroprotective effect of these treatments one needs to have better understanding in the field of neurodegenerative processes.